Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review

Journal of Obesity & Metabolic Syndrome, Год журнала: 2023, Номер 32(3), С. 197 - 213

Опубликована: Сен. 13, 2023

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for associated with metabolic syndrome. MASLD most common cause of chronic and leading liver-related morbidity mortality. It important that all stakeholders be involved in tackling public health threat obesity obesity-related diseases, including MASLD. A simple clear assessment referral pathway using non-invasive tests essential to ensure patients severe are identified referred specialist care, while less remain primary where they best managed. While lifestyle intervention cornerstone management MASLD, cardiovascular risk must properly assessed managed because No pharmacological agent has been approved treatment but novel anti-hyperglycemic drugs appear have benefit. Medications used diabetes other conditions may need adjusted as progresses cirrhosis, especially decompensated cirrhosis. Based on tests, concepts compensated advanced clinically significant portal hypertension provide a practical approach stratifying according complications can help manage such patients. Finally, prevention sarcopenia should considered

Язык: Английский

---

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications

Gut, Год журнала: 2024, Номер unknown, С. gutjnl - 330595

Опубликована: Янв. 16, 2024

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic globally and is currently estimated to affect up 38% of global adult population. NAFLD a multisystem where systemic insulin resistance related metabolic dysfunction play pathogenic role in development its relevant liver-related morbidities (cirrhosis, failure hepatocellular carcinoma) extrahepatic complications, such as cardiovascular (CVD), type 2 diabetes mellitus, kidney disease, certain types cancers. In 2023, three large multinational associations proposed that dysfunction-associated steatotic (MASLD) should replace term NAFLD; name chosen non-alcoholic steatohepatitis was (MASH). Emerging epidemiological evidence suggests an excellent concordance rate between MASLD definitions—that is, ~99% individuals with meet criteria. this narrative review, we provide overview literature on (a) recent data risk developing CVD malignant (b) underlying mechanisms by which (and factors strongly linked MASLD) may increase these complications (c) diagnosis assessment potential treatments reduce people or MASH.

Язык: Английский

---

Current status and future trends of the global burden of MASLD

Trends in Endocrinology and Metabolism, Год журнала: 2024, Номер 35(8), С. 697 - 707

Опубликована: Фев. 29, 2024

Язык: Английский

---

Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease

Gut, Год журнала: 2023, Номер unknown, С. gutjnl - 331003

Опубликована: Окт. 31, 2023

Objective We explored clinical implications of the new definition metabolic dysfunction-associated steatotic liver disease (MASLD) by assessing its prevalence and associated cardiovascular (CVD) risk. Design From nationwide health screening data, we identified 9 775 066 adults aged 20–79 who underwent examination in 2009. Participants were categorised into four mutually exclusive groups: (1) MASLD; (2) MASLD with increased alcohol intake (MetALD); (3) other combined aetiology (the three collectively referred to as MASLD/related (SLD)); (4) no SLD. SLD was determined fatty index ≥30. The primary outcome CVD event, defined a composite myocardial infarction, ischaemic stroke, heart failure or death. Results MASLD, MetALD 27.5%, 4.4% 1.5%, respectively. A total 8 808 494 participants without prior followed up for median 12.3 years, during which 272 863 events occurred. cumulative incidence multivariable-adjusted risk higher than those (HR 1.38 (95% CI 1.37 1.39)). Multivariable-adjusted HR CI) 1.39 (1.38 1.40) 1.28 (1.26 1.30) 1.30 1.34) compared absence any these conditions. also non-alcoholic respective condition. Conclusion Over one-third Korean have bear high

Язык: Английский

---

Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021

EClinicalMedicine, Год журнала: 2024, Номер 76, С. 102848 - 102848

Опубликована: Сен. 24, 2024

Язык: Английский

---

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies

Pharmacological Reviews, Год журнала: 2024, Номер 76(3), С. 454 - 499

Опубликована: Янв. 30, 2024

Steatotic liver disease (SLD) displays a dynamic and complex phenotype. Consequently, the metabolic dysfunction-associated steatotic (MASLD)/metabolic steatohepatitis (MASH) therapeutic pipeline is expanding rapidly in multiple directions. In parallel, non-invasive tools for diagnosing monitoring responses to interventions are being studied, clinically feasible findings explored as primary outcomes interventional trials. The realization that distinct subgroups exist under umbrella of SLD should guide more precise personalized treatment recommendations facilitate advancements pharmacotherapeutics. This review summarizes recent updates pathophysiology-based nomenclature outlines both effective pharmacotherapeutics those MASLD/MASH, detailing their mode action current status phase 2 3 clinical Of extensive arsenal MASLD/MASH pipeline, several have been rejected, whereas other, mainly monotherapy options, shown only marginal benefits now tested part combination therapies, yet others still development monotherapies. Although successful drug candidate (or combinations) remains elusive, such approaches will ideally target MASH fibrosis while improving cardiometabolic risk factors. Due urgent need novel strategies potential availability safety tolerability data, repurposing existing approved drugs an appealing option. Finally, it essential highlight and, by extension, MASLD be recognized approached systemic affecting organs, with vigorous implementation interdisciplinary coordinated plans. Significance Statement SLD, including, among others, MASH, considered most prevalent chronic condition than one-fourth global population. aims provide information regarding pathophysiology, diagnosis, management line guidelines Collectively, hoped provided furthers understanding state direct implications stimulates additional research initiatives.

Язык: Английский

---

MAFLD predicts cardiovascular disease risk better than MASLD

Liver International, Год журнала: 2024, Номер 44(7), С. 1567 - 1574

Опубликована: Апрель 20, 2024

Abstract Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic fatty (MAFLD). We compared abilities MAFLD MASLD to predict risk atherosclerotic cardiovascular (ASCVD). Methods Six thousand ninety six participants from 2017 2020 National Health Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen study. The associations between status coronary surrogates, such 10‐year ASCVD self‐reported events, analysed. Results identified in 2911 (47.7%) 2758 (45.2%) patients, respectively. (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high than (OR: 1.82, CI, 1.52–2.18, comparison absence each condition. However, MAFLD, alone not increased risk. Multiple logistic regression revealed that significantly 2.82; CI: 1.13–7.01; .03) alone. Conclusions Although both different risks, predicted better MASLD. higher predictive ability attributed dysfunction rather moderate alcohol use.

Язык: Английский

---

The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus

Metabolism, Год журнала: 2024, Номер 161, С. 156028 - 156028

Опубликована: Сен. 11, 2024

Язык: Английский

---

Glycolipid Metabolic Disorders, Metainflammation, Oxidative Stress, and Cardiovascular Diseases: Unraveling Pathways

Biology, Год журнала: 2024, Номер 13(7), С. 519 - 519

Опубликована: Июль 12, 2024

Glycolipid metabolic disorders (GLMDs) are various resulting from dysregulation in glycolipid levels, consequently leading to an increased risk of obesity, diabetes, liver dysfunction, neuromuscular complications, and cardiorenal vascular diseases (CRVDs). In patients with GLMDs, excess caloric intake a lack physical activity may contribute oxidative stress (OxS) systemic inflammation. This study aimed review the connection between GLMD, OxS, metainflammation, onset CRVD. GLMD is due causing dysfunction synthesis, breakdown, absorption glucose lipids body, excessive ectopic accumulation these molecules. mainly neuroendocrine dysregulation, insulin resistance, metainflammation. many inflammatory markers defense cells play vital role related tissues organs, such as blood vessels, pancreatic islets, liver, muscle, kidneys, adipocytes, promoting lesions that affect interconnected organs through their signaling pathways. Advanced glycation end products, ATP-binding cassette transporter 1, Glucagon-like peptide-1, Toll-like receptor-4, sphingosine-1-phosphate (S1P) crucial since they glucolipid metabolism. The consequences this system organ damage morbidity mortality.

Язык: Английский

---

Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease

Gut, Год журнала: 2024, Номер 73(11), С. 1883 - 1892

Опубликована: Авг. 1, 2024

Background Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD). Aim To explore the effects of statins on long-term risk all-cause mortality, liver-related clinical events (LREs) and stiffness progression MASLD. Methods This cohort study collected data MASLD undergoing at least two vibration-controlled transient elastography examinations 16 tertiary referral centres. Cox regression analysis was performed to examine association between statin usage mortality LREs stratified by compensated advanced chronic (cACLD): baseline measurement (LSM) ≥10 kPa. Liver defined as an LSM increase ≥20% for cACLD from <10 kPa or non-cACLD. reduction decrease cACLD. Results We followed up 7988 5.9 (IQR 4.6–8.2) a median 4.6 years. At baseline, 40.5% used statins, present 17%. Statin significantly associated lower (adjusted HR=0.233; 95% CI 0.127 0.426) HR=0.380; 0.268 0.539). also rates (HR=0.542; 0.389 0.755) non-cACLD HR=0.450; 0.342 0.592), but not HR=0.914; 0.778 1.074). Conclusions relatively

Язык: Английский

---